Quarterly report pursuant to Section 13 or 15(d)

Revenues from Contracts and Significant Customers (Company's product revenue) (Details)

v3.23.3
Revenues from Contracts and Significant Customers (Company's product revenue) (Details) - USD ($)
$ in Thousands
 3 Months Ended 9 Months Ended
Sep. 30, 2023
Sep. 30, 2022
Sep. 30, 2023
Sep. 30, 2022
Product revenue, net $ 15,279 $ 16,043 $ 44,405 $ 55,074
Collaboration revenue 182 364 546 1,518
Other revenue 19,260 73 19,519 2,629
Net revenue 34,752 16,528 64,567 59,339
Related Party        
Revenue - related party 31 48 97 118
Qbrexza        
Product revenue, net 5,865 6,265 18,038 19,752
Other revenue   19,000 2,500 19,000
Accutane        
Product revenue, net 4,882 4,121 15,109 14,228
Amzeeq        
Product revenue, net 2,336 1,161 4,904 5,892
Zilxi        
Product revenue, net 681 554 1,567 1,851
Targadox        
Product revenue, net 929 1,168 2,386 6,558
Exelderm        
Product revenue, net 764 1,001 1,813 3,018
Ximino        
Product revenue, net (199) $ 1,773 567 $ 3,775
Luxamend        
Collaboration revenue $ 21   $ 21